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Abstract
Introduction: Differentiation between steatosis and non-alcoholic steatohepa-
titis (NASH) in non-alcoholic fatty liver disease (NAFLD) is important as
NASH progress to cirrhosis. No specific laboratory/imaging technique exists
either to diagnose NASH or to select patients for liver biopsy. Patients and
methods: We evaluated serum ferritin and the features of metabolic syndrome
with respect to histological inflammation and/or fibrosis in NAFLD patients.
The Kleiner scoring system was used to classify NAFLD in consecutive liver
biopsies. One hundred and eleven patients: median age 52.6, 64 males, obesity
62, diabetes mellitus (DM) 58, arterial hypertension 26 and hyperlipidaemia
40%. Results: Histologically, 40.7 had fatty liver, 30.6% had borderline NASH,
28.7% had NASH and 11% had cirrhosis. Multivariate regression showed that
diabetes, serum ferritin concentrations, body mass index (BMI) and ASTwere
independently associated with NASH: together, the areas under the receiver
operating characteristic (AUROC) was 0.91 (95% confidence interval
0.86–0.96); fibrosis was associated with ferritin concentrations and BMI:
AUROC 0.87, portal inflammation with ferritin and DM: AUROC 0.82, while
lobular inflammation was associated with BMI, DM and ferritin: AUROC
0.85. Conclusion: Serum ferritin concentrations and BMI are strongly asso-
ciated with fibrosis, portal and lobular inflammation in NAFLD patients. Both
ferritin and BMI are potential discriminant markers to select patients for liver
biopsy and are associated with inflammation and fibrosis.
Non-alcoholic fatty liver disease (NAFLD), encompass-
ing simple steatosis, non-alcoholic steatohepatitis
(NASH) to cirrhosis, is emerging as one of the most
common liver disorders in developed countries (1). In
the UK, 34 and 32% of patients with unexplained
abnormal liver function tests are subsequently diagnosed
as having NASH or fatty liver, respectively, by liver biopsy
(2). Although fatty liver is now established to have a
benign clinical course (3), NASH can be a cause of
progressive liver fibrosis leading to cirrhosis, liver failure
and hepatocellular carcinoma (4, 5).
Severe fibrosis is noted in 7–49% of NASH patients
and cirrhosis develops in 2–28% (6–10). Those at a high
risk of progression include patients with histological
advanced fibrosis (5, 11). The diagnosis of NAFLD is
clinicopathological and, therefore, although the clinical
component of the diagnosis is one of exclusion of
significant alcohol ingestion and other causes of chronic
liver disease, the histopathological examination is vital in
diagnosing and staging suspected NAFLD (12). The
important distinction is between fatty liver alone and
NASH (i.e. inflammation with or without fibrosis).
Given the prevalence of fatty liver, a liver biopsy cannot
be considered for all patients. Indeed, in a recent study of
an Italian group, fatty liver regressed in 50% of all cases
examined and had a benign course (13). Therefore, there
have been efforts to determine the predictive markers of
fibrosis and/or steatohepatitis with the intention of
avoiding biopsies, but to date, none have good clinical
applicability (14).
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The factors associated with NASH are documented in
several studies: male gender, high levels of ALT and AST,
g-glutamyl transferase (g-GT), triglycerides, type II dia-
betes mellitus (DM), systemic hypertension and serum
acute-phase proteins (9, 15–18).
Non-alcoholic fatty liver disease is also associated with
insulin resistance syndrome or recently characterized
metabolic syndrome (19), which is associated with
insulin resistance (15, 20), diabetes (7, 16), obesity (17)
and hyperlipidaemia (7, 15, 18). There is a close relation-
ship between NAFLD and several features of the meta-
bolic syndrome (21, 22).
Serum ferritin is an acute-phase protein and concen-
trations are increased, in the absence of iron overload,
where there is inflammation, liver necrosis and alcohol
abuse (23). An increased concentration of serum ferritin
in the presence of normal transferrin saturation and
normal values of serum iron is usually considered to be
iron independent even when the cause of the increase is
unknown (24). With regard to NAFLD, increased values
of serum ferritin have been reported in patients with DM
(25, 26), in subjects with insulin resistance often exhibit-
ing metabolic abnormalities (27) – i.e. high diastolic
blood pressure, HDL levels, high glucose and insulin
resistance (28) – and also in NASH patients (7, 29–32).
In NAFLD, increased ferritin levels are considered to
be an expression of metabolic syndrome and of hepatic
damage because of inflammatory cytokine activation
(33), although another group assumes that the associa-
tion between ferritin and the components of the meta-
bolic syndrome may be mediated by undiagnosed
NAFLD (34). There are several studies evaluating NASH
and increased serum ferritin levels (28, 35). However,
there is no consensus as to whether increased ferritin
concentrations are associated with severe fibrosis among
NAFLD patients (Table 1), and indeed, a current review
of non-invasive markers does not mention or consider
serum ferritin (14).
The purpose of this study was firstly to establish the
frequency of increased serum ferritin concentrations
in patients with NAFLD and its association with the
components of the metabolic syndrome, And secondly,
to evaluate whether these associations (if established)
could be used as predictive factors to identify patients
with inflammation or fibrosis, to differentiate them from
patients with simple fatty liver and thus be a guide as to
which patients should have a liver biopsy.
Methods
Patients and liver biopsies
We evaluated consecutive patients whose liver biopsies had
a database with the keywords steatosis and/or steatohepa-
titis as a pathological diagnosis compatible with NAFLD,
and reviewed their clinical records. There were 355 such
patients. The following variables were recorded: sex, age,
renal and thyroid function, blood count, coagulation
screen, iron studies, liver enzymes, fasting lipid profile,
fasting glucose, HbA1c, alkaline phosphatase (ALP), albu-
min, creatinine kinase, serum ferritin and C-reactive
protein (CRP) as well as urate and body mass index
(BMI). Clinical data and blood test results for the patients
included in our study were collected within 1 month from
the time of the liver biopsy. Patients who did not have such
data available were excluded from the study population.
Associations with specific histopathological findings
were evaluated by univariate and multivariate logistic
regression.
Other types of chronic liver disease were excluded using
serological markers for viral hepatitis, autoantibodies, HFE
testing and measuring copper and ceruloplasmin and
a-1-antitrypsin concentrations. Patients were considered
to have DM if they were receiving drug treatment for this
disease or they had fasting glucose levels 47mmol/l. They
were defined as being hypertensive if their blood pressure
was 130/85mmHg or if they were receiving treatment for
previously diagnosed hypertension. BMI was calculated as
weight (kg) divided by squared height (m2).
Patients with thyroid dysfunction or taking thyroxine
and patients consuming 421U (males) or 14U
(females) of alcohol per week were excluded. Patients
were also excluded if they had a history of ingestion of
drugs known to cause steatohepatitis such as corticoster-
oids, methotrexate or oestrogens.
The upper normal limit for ALT was considered to be
31U/ml as given by our laboratory. Sensitivity analysis
was also performed using the proposed upper normal
limits of 30U/ml for males and 19U/ml for females (48).
Similarly, serum ferritin differs between males and fe-
males, although we performed sensitivity analysis using
the upper normal limits of 340 mg/l for males and 150 mg/
l for females.
Histology was reviewed and histological variables were
graded following the previously published Kleiner Score
(49). Briefly, steatosis was graded 0–3 as follows: low- to
medium-power evaluation of parenchymal involvement
by steatosis o5, 5–33%, 433–66% and 466% repre-
senting 0, 1, 2 and 3 respectively. Fibrosis was staged
as 0 representing none, 1, 1A, 1B and 1C representing
perisinusoidal or periportal, mild zone 3 perisinusoidal,
moderate zone 3 perisinusoidal portal/periportal retro-
spectively, perisinusoidal and portal/periportal 2, brid-
ging fibrosis 3, cirrhosis 4.
Lobular inflammation was defined as an overall assess-
ment of all inflammation: no foci as 0o 2 foci per  200
field as 1, 2–4 foci per  200 field as 2, 44 foci per
 200 field as 3. Portal inflammation was assessed from
lowmagnification: none to minimal as 0 and greater than
minimal as 1. We did not consider microgranulomas or
lipogranulomas as inflammation.
In our study, all cases were categorized by two pathol-
ogists (F. G. and J. W.), blinded to clinical findings, as
NAFLD with only steatosis, NASH as having inflamma-
tion1/ fibrosis and borderline cases that did not quite
fulfil the diagnostic criteria for NASH (50). Patients were
placed into two groups: the first group including the
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NASH patients and the second group including the non-
NASH patients. The latter presented with either NAFLD
or those cases that were thought to be borderline. This
was done so as to have a definitive diagnosis of NASH
and hence have a basis for predictive evaluation, as
clinically, these patients would be the ones to be con-
sidered for liver biopsy. Additionally, we assigned two
groups of fibrosis, basing our assessment on the Kleiner
score: group 1 (none or mild fibrosis), which included 0,
1 and 1A, and group 2 (moderate fibrosis to cirrhosis),
which included 1B, 1C, 2, 3 and 4.
Statistical analysis
Descriptive statistics were performed on all study para-
meters [mean, standard error of means (SEM), range].
All continuous variables were tested for normality. All
normally distributed data were analysed using a t-test.
Categorical data and derived proportions were analysed
using the chi-square test to compare NASH vs no NASH,
fibrosis none-mild vs severe-cirrhosis and inflammation
vs minimal inflammation.
Diagnostic values for diagnosis, fibrosis and inflam-
mation in NASH were assessed using sensitivities, speci-
ficities, positive and negative predictive values and the
areas under the receiver operating characteristic (AUR-
OC) curves. Stepwise logistic regression was performed
to assess the variables associated with diagnosis, fibrosis
and inflammation. A P value o0.05 was considered to be
significant in the univariate and multivariate analysis.
A normogram was derived using the predictors from
the multivariate analysis for fibrosis and inflammation
separately, so as to relate the risk of fibrosis to increasing
concentrations of serum ferritin.
Table 1. List of studies evaluating the correlation between serum ferritin and severe fibrosis among non-alcoholic fatty liver disease patients
Author Study population Aim of the study Conclusion
Bugianesi et al.
(36)
132 HCV patients with a
matched cohort of 132 NAFLD
patients
Identify the possible serological
determinants of histological differences
Severe fibrosis was predicted by steatosis,
ferritin, insulin resistance
Bugianesi et al.
(37)
263 prospectively enrolled
NAFLD patients
Define the impact of iron overload,
genetic mutations of HFE and insulin
resistance on the severity of liver fibrosis
in NAFLD patients
Ferritin independently associated with fibrosis
after adjusting for age, sex and BMI
Ledinghen et al.
(38)
67 patients retrospectively
included
Evaluate the prevalence of fibrosis and
NASH in patients with accidentally
detected elevated ALT
Ferritin was significantly different between
FZ2 and Fo 2 groups (Metavir)
Giostra et al.
(39)
505 obese patients at the time
of gastric by-pass surgery
Identification of factors to select patients
at risk of NASH for liver biopsy
Insulin resistance, DM, ferritin could predict
patients with NASH
Loguercio et al.
(40)
Prospectively enrolled 305
NAFLD patients
Define the characteristics of Italian NAFLD
patients
Ferritin correlated univariately with liver
fibrosis and inflammation
Moon et al. (41) 39 NAFLD patients Evaluate the association between serum
and hepatic iron deposition with hepatic
fibrosis or inflammation
Ferritin and BMI associated with inflammation
and fibrosis univariately
Canbakan et al.
(42)
105 NAFLD patients studied,
follow-up 6 months
Comparative analysis between clinical,
biochemical and histological variables of
NAFLD
Serum ferritin has prognostic significance in
liver damage and fibrosis. DM is predictive of
advanced fibrosis and inflammation
Shimada et al.
(43)
81 patients with biopsy-proven
NASH
Identify features of NASH and risk factors
for severe fibrosis
Significant difference of serum ferritin
between mild and severe fibrosis but in an
adverse way
Angulo et al.
(44)
144 biopsy-proven NAFLD
patients
Identify independent predictors of severe
hepatic fibrosis in NASH
Older age, obesity and DM help identify those
NASH patients at risk of severe liver fibrosis
Koruk et al. (45) 18 NASH patients compared
with 16 normal controls
Levels of acute-phase proteins in NASH
patients and relation to histopathology
No relation between ferritin and the degree of
steatosis, inflammation, liver fibrosis in NASH
patients
Albano et al.
(46)
167 NAFLD patients and 59
controls
Association between immune reactions
(because of oxidative stress) and stage of
NAFLD
Immune reactions triggered by oxidative stress
can be an independent predictor of advanced
fibrosis
Fierbinteanu-
Braticevici et al.
(47)
80 NASH patients Assess the risk factors of fibrosis in NASH Age, BMI, ALT, glucose and triglycerides, Perls’
grade and the serum index of oxidative stress
(MDA and GSH) are independent risk factors
for fibrosis in NASH
ALT, alanine aminotransferase; BMI, body mass index; DM, diabetes mellitus; GSH, glutathione; HCV, hepatitis C virus; MDA, malondialdehyde; NAFLD,
non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis.
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The SPSS version 12.0 was used for the statistical
analysis.
Results
Patients
There were 111 biopsies from 111 patients who fulfilled
the inclusion criteria. The median age was 52.6 years
(range: 21–72 years) and 71 patients were men (64%).
Obesity was present in 73 (66%) (BMI425) while 64
(58%) had DM, 29 (26%) arterial hypertension, 60 (54%)
abnormal cholesterol (45.2mmol/l) and 47 (42%) had
increased triglycerides (42.3mmol/l). Ferritin was ab-
normal in 27 (24.5%) of our population (4340 ng/ml)
and CRP in 48 (43%) (45). With regard to liver function
tests, ALT was normal in 12 (11.1%), AST in 23 (20.6%)
and g-GT in 15 (13.9%). Total bilirubin was within the
normal range in 91 (82.2%), albumin in 102 (92.5%) and
ALP in 92 (82.5%). Only one male patient had ALT
between 30 and 31 IU/l and three females between 19
and 31 IU/l, so that using the cutoff by Prati made no
difference to the analyses below (48).
Histologically, the diagnosis was fatty liver in 45
(40.7%), borderline NASH in 34 (30.6%) and NASH in
32 (28.7%); regarding fibrosis, 14 (13%) had perisinu-
soidal and portal/periportal fibrosis, 10 (9.3) bridging
fibrosis and 12 (11.1%) had established cirrhosis. Mini-
mal portal inflammation was present in 56 (50.9) and 15
(13.9%) had prominent ballooning. Lobular inflamma-
tion was scored as 3, 2 and 1 in 0.9, 20.4 and 50% of our
study group respectively. There was no lobular inflam-
mation in 28.7% of our patients (Table 2).
Non-alcoholic steatohepatitis diagnosis
There were no statistical differences between NAFLD
patients with or without NASH with regard to age,
gender, arterial hypertension, hyperlipidaemia and cho-
lesterol. There were also no differences for serum urate,
ALT, g-GT, total bilirubin, albumin, ALP, CRP, serum
iron and TIBC (Table 3).
Interestingly, in those with normal LFTs, serum ferri-
tin was higher than normal in 15% with simple fatty liver
and 24% with NASH. Univariate analysis revealed that
BMI, DM, ferritin and AST were significantly associated
with the diagnosis of NASH. Forward regression analysis
showed that diabetes status, ferritin concentrations, BMI
and AST were independently associated with a diagnosis
of NASH (Table 4). ROC curve combining these four
variables (BMI, ferritin, diabetes, AST) was derived from
regression analysis for the diagnosis of NASH. The area
under the ROC curve was 0.91 [95% confidence interval
(CI) 0.86–0.96] (Fig. 1).
Fibrosis
In relation to fibrosis, patients’ characteristics are shown
in Table 5. BMI, ferritin, DM, g-GT, AST and CRP
showed a significant association with fibrosis in univari-
ate analysis. Interestingly, the AST was significantly
higher in NASH patients with severe fibrosis. In the
multivariate analysis, forward regression analysis showed
that ferritin concentrations and BMI were the only two
variables independently associated with fibrosis (Table
4). The area under the ROC curve of independent
predictors, BMI and ferritin, for the diagnosis of fibrosis
was 0.87 (95% CI 0.80–0.93) (Table 6).
When patients with cirrhosis (11%) were excluded
from our study group, then BMI, ferritin as well as DM
were the three variables predicting fibrosis in the multi-
variate analysis. The area under the ROC curve for these
three predictors was 0.85 (95% CI 0.78–0.93) (Table 6).
Inflammation
In the univariate analysis, portal inflammation correlated
with ferritin, DM, total bilirubin, triglycerides and total
iron-binding capacity. In the multivariate analysis, ferri-
tin and DM were again significant. The ROC curve of
ferritin and DM showed that the area under the curve
was 0.816 (95% CI 0.736–0.896) (Tables 4 and 6).
Lobular inflammation showed a univariate correlation
with AST, BMI, DMand ferritin. Logistic regression showed
that ferritin, DMand BMIwere significantly associated with
lobular inflammation. The area under the ROC curve was
0.848 (95% CI 0.778–0.918) (Tables 4 and 6).
Interestingly, serum ferritin at a cut-off value of
240 ng/ml and above (derived from the ROC curve), in a
Table 2. Histological findings in a consecutive cohort of biopsies
with non-alcoholic fatty liver disease
Grade/
stage
Steatosis
(%)
Fibrosis
(%)
Inflammation
(%) Diagnostic
classification
(%)Lobular Portal
0 3.7 41.7 28.7 49.1 40.7
1 30.6 25 50 50.9 30.6
2 43.5 13 20.4 28.7
3 22.2 9.3 0.9
4 11.1
Histological variables scored according to Kleiner and colleagues (%).
We used the descriptive scoring system for histological variables in
NAFLD established by Kleiner and colleagues. Steatosis was graded 0–3
as follows: low- to medium-power evaluation of parenchymal involve-
ment by steatosis o 5%, 5–33%, 4 33–66%, 4 66% representing 0,
1, 2, 3 respectively. Fibrosis was staged as 0 representing none, 1, 1A, 1B
and 1C representing perisinusoidal or periportal, mild zone 3 perisinu-
soidal, moderate zone 3 perisinusoidal portal/periportal retrospectively,
perisinusoidal and portal/periportal 2, bridging fibrosis 3, cirrhosis 4.
Lobular inflammation was defined as overall assessment of all inflamma-
tion: no foci as 0o 2 foci per  200 field as 1, 2–4 foci per  200 field as
2, 4 4 foci per  200 field as 3. Portal inflammation was assessed from
low magnification: none to minimal as 0, greater than minimal as 1:
categories were assigned as: not steatohepatitis (NASH) (1), borderline/
possible steatohepatitis (NASH) (2) and definite steatohepatitis (NASH)
(3) for the study.
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Table 3. Anthropometric, clinical and laboratory data of patients with fatty liver and steatohepatitis
Normal values Total Fatty liver NASH P
Number, n (%) 111 (100%) 47 (42.3%) 64 (57.7%)
Age (at biopsy) 54 14 5313 5412 NS
Gender (male) 63.9% 72.7% 60% NS
BMI o28 kg/m2 28.2 5 25.32.8 29.23.9 0.000
DM 58.3% 27.3% 73% 0.001
Arterial hypertension 130/85 mmHg 26.2% 36.1% 40.6% NS
Serum biochemical markers
Glucose o6.1 mmol/l 4.9 1.2 4.61.1 5.22.1 NS
Triglycerides o2.3 mmol/l 2.4 1.3 2.31.5 2.41.0 NS
HDL 41 mmol/l 1.4 0.5 1.30.4 1.50.6 NS
LDL o3 mmol/l 2.9 0.9 2.90.9 3.10.9 NS
Cholesterol o5 mmol/l 5.4 1.2 5.31.3 5.51.1 NS
AST o31 U/l 49 24 369 558 0.002
ALT o31 U/l 70 39 6511 7213 NS
g-GT 5–36 U/l 98 58 8417 11313 NS
TBL o19mmol/l 13.5 9 1510 128 NS
ALP 35–129 U/l 94 46 9319 9711.8 NS
Albumin 35–50 g/l 45 4.4 454 454.5 NS
CRP 0–5 mg/l 5.3 4.4 4.63.5 6.33.1 NS
Ferritin 40–340mg/l 228 100 14626 30926 0.000
Fe 11–36mmol/l 20 7 19.66 19.86.9 NS
TIBC 53–85mmol/l 58 10 58.210 57.810 NS
Urate 0.1–0.4 mmol/l 0.31 0.1 0.280.1 0.370.1 NS
Values are expressed in mean SE or number (n) or percent of patients (%).
Statistically significant in univariate analysis.
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CRP, C-reactive protein; DM,
diabetes mellitus, Fe, serum iron; g-GT, gamma-glutamyl transferase; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NS, non-significant;
TBL, total bilirubin; TIBC, total iron-binding capacity.
Table 4. Independent predictors of non-alcoholic steatohepatitis (diagnosis), liver fibrosis and inflammation in patients with non-alcoholic fatty
liver disease in the multivariate logistic regression analysis
95% CI for Exp (B)
Diagnosis B SE Sig. Odds ratio Lower Upper
BMI 0.157 0.098 0.001 1.398 1.229 2.279
DM 0.007 0.002 0.002 1.007 1.001 1.021
AST  2.536 0.659 0.000 0.079 0.020 0.721
Ferritin 0.033 0.017 0.05 1.034 1.003 1.161
Constant  8.095 2.779 0.004 0.000
Fibrosis
BMI 0.236 0.103 0.022 1.266 1.035 1.550
Ferritin 0.016 0.004 0.000 1.016 1.007 1.024
Constant 10.119 3.162 0.001 0.000
Portal inflammation
DM 1.101 0.420 0.009 3.007 1.319 6.853
Ferritin 0.019 0.009 0.035 1.019 1.008 1.022
Constant  4.726 1.983 0.017 0.009
Lobular inflammation
BMI 0.187 0.077 0.014 1.066 1.038 1.401
DM 2.163 0.626 0.001 0.115 0.034 0.392
Ferritin 0.054 0.020 0.007 1.056 1.015 1.099
Constant  7.706 2.933 0.009 0.000
The independent effects of significant variables on diagnosis, fibrosis and inflammation were assessed by multiple regression analysis with forward
stepwise selection procedures.
In our study, we defined NASH as steatohepatitis, whereas borderline NASH and fatty liver were defined as no NASH.
AST, aspartate aminotransferase; B, estimated co-efficient; BMI, body mass index; CI, confidence intervals; DM, diabetes mellitus; NASH, non-alcoholic
steatohepatitis; SE, standard error; sig., significance.
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multivariate logistic regression, was significantly asso-
ciated with stage (P= 0.034), lobular inflammation
(P= 0.009) and portal inflammation (P= 0.043). Indeed,
above a serum ferritin of 240 ng/ml, 62% of those
patients with normal liver function tests had NASH.
The cut-off value of serum ferritin at 240 ng/ml ferritin
showed a sensitivity of 91% and a specificity of 70% in
ascertaining the presence of fibrosis and/or inflammation
in NAFLD patients. The area under the ROC curve with
respect to a cutoff of 240 ng/ml ferritin evaluating the
combination of fibrosis and the two features of inflam-
mation, i.e. NASH was 0.82 (95% CI 0.73–0.90) (Fig. 2).
When females were evaluated separately frommales, as
the normal range of serum ferritin is lower, there were no
differences with males, possibly because most females
were post-menopausal (83%). In addition, the compo-
nents of the metabolic syndrome were distributed with-
out significant differences between males and females.
Discussion
As it is not practical to perform a liver biopsy in every
patient with suspected NAFLD, patients are selected for
biopsy, sometimes based on ultrasound appearances,
lower than the normal platelet count (suggesting possible
portal hypertension) or particular features of the meta-
bolic syndrome (e.g. diabetes or obesity) as these features
are potentially associated with worse disease (51). It is
important to identify NAFLD patients with fibrosis or
solely inflammation in association with fatty liver be-
cause long-term studies suggest that the presence of
NASH is of prognostic importance (52).
Despite the use of non-invasive markers of chronic
liver disease, such as serum markers and transient
elastography, liver biopsy remains the gold standard for
the assessment of fibrosis in NAFLD (14, 53). The
NAFLD patients included in our retrospective study were
similar to other cohorts in the literature. In particular,
those with normal liver function tests had simple fatty
Fig. 1. ROC curve for the diagnosis of NASH using serum ferritin,
BMI, diabetes and serum AST. ROC curve of independent predictors
derived from regression analysis for the diagnosis of NASH. The
diagonal line represents what is achieved by chance alone. The area
under the ROC curve is 0.91 (95% CI 0.86–0.96). We defined NASH
as steatohepatitis, whereas borderline NASH and fatty liver were
defined as no NASH. AST, aspartate aminotransferase; BMI, body
mass index; CI, confidence interval; NASH, non-alcoholic
steatohepatitis; ROC, receiver operating characteristic curve.
Table 5. Anthropometric, clinical and laboratory data of patients
with none to mild fibrosis or moderate fibrosis to cirrhosis
Normal
values
Fibrosis
none-mild
Fibrosis
moderate-
cirrhosis P
Number, n (%) 60% 40%
Age (at biopsy) 46.7 14 49.5 7.7 NS
Gender (male) 63.6% 66.6% NS
BMI o 28 kg/m2 26.4 3.3 30.3 4.4 0.001
DM 42.4% 71.4% 0.006
Arterial hypertension 130/85 mmHg 39.4% 40.5% NS
Serum biochemical markers
Glucose o 6.1 mmol/l 5.5 0.7 6.1 0.9 NS
Triglycerides o 2.3 mmol/l 2.4 1.1 2.5 1 NS
HDL 4 1 mmol/l 1.5 0.6 1.4 0.5 NS
LDL o 3 mmol/l 2.9 0.9 2.9 1.0 NS
Cholesterol o 5 mmol/l 5.1 0.8 5.3 1.3 NS
AST o 31 U/l 44 16 64 22 0.000
ALT o 31 U/l 72 22 73 21 NS
g-GT 5–36 U/l 72 11 182 38 0.003
TBL o 19 mmol/l 11 6 12 5 NS
ALP 35–129 U/l 68 18 77 28 NS
Albumin 35–50 g/l 47 3 49 6 NS
CRP 0–5 mg/l 5.5 2.1 6.1 2.7 0.04
Ferritin 40–340 mg/l 117 19 377 27 0.000
Fe 11–36 mmol/l 18.8 7.3 21.3 2.12 NS
TIBC 53–85 mmol/l 57.8 11.3 60.5 0.7 NS
Urate 0.1–0.4 mmol/l 0.3 0.1 0.4 0.1 NS
Values are expressed in mean SD or number (n) or per cent of
patients (%).
Statistically significant in univariate analysis.
For abbreviations, see footnote in Table 3.
Table 6. Characteristics of receiver operating characteristic curves
for fibrosis, portal and lobular inflammation
State variable Test variable AUROC 95% CI
Fibrosis Ferritin and BMI 0.87 0.800.93
Fibrosis (excluded
cirrhotic patients)
Ferritin, BMI, DM 0.85 0.780.93
Portal
inflammation
Ferritin and BMI 0.82 0.740.90
Lobular
inflammation
Ferritin, BMI, DM 0.85 0.780.92
AUROC, area under the ROC curve; BMI, body mass index; CI, con-
fidence intervals; DM, diabetes mellitus; ROC, receiver operating char-
acteristic curve.
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liver in 24% and NASH in 15%. Thus, our patients are
representative of NAFLD patients seen in other studies
including prospective ones from various countries (36,
40, 44, 47).
In this study, we showed that increased concentrations
of serum ferritin are an independent predictor of fibrosis
(78% sensitivity, 50% specificity) and inflammation,
both portal (78% sensitivity, 60% specificity) and lobular
(85% sensitivity, 67% specificity). In this context, it is the
sensitivity that is useful, as in clinical practice, other
forms of liver disease are excluded by routine laboratory
assays. Thus, these findings could aid the clinician in the
selection of which NAFLD patients should have a liver
biopsy.
Using the cutoff of serum ferritin 240 ng/ml or more,
and a BMI 428.2, this combination identified patients
at risk of having fibrosis with an 82% sensitivity and a
79% specificity. Interestingly, when patients with cirrho-
sis (11%) were excluded from the study group, and
applying the same cutoffs, fibrosis was predicted with a
90% sensitivity and a 72% specificity in diabetic patients
and 86% sensitivity and 77% sensitivity in the entire
study group.
Our results could be used to test the clinical utility
of serum ferritin concentrations in decision making
regarding a liver biopsy in patients with clinically diag-
nosed NAFLD (Figs 3 and 4). In particular, the associa-
tion of an increased BMI 428.2 and increased ferritin
4240 ng/ml seems to indicate a particularly high risk of
NASH, and in the face of a normal ALT, being obese
but with a ferritin of 240 ng/ml or more is associated
with NASH in 62% of cases. Moreover, using four
variables consisting of serum ferritin, DM, BMI and
AST, we could predict NASH with a sensitivity of 92 and
a specificity of 80%.
In a recently published study (54), the characteristics
of 823 patients with biopsy-proven NAFLD were ana-
lysed retrospectively. The authors compared two groups
of patients similar to our comparison groups and con-
cluded that BMI Z28, AST/ALT ratio Z0.8, and the
presence of diabetes are independent predictive factors
for severe fibrosis. Combining these variables, a clinical
scoring system was devised for predicting severe fibrosis
in NAFLD patients (54).
However, in a recently published review (53), com-
menting on the use of non-invasive tests to predict
hepatic fibrosis in NAFLD patients, it was highlighted
that prospective validation of these clinical scoring
systems is lacking.
Fig. 2. ROC curve using a cutoff for serum ferritin of 240mg/l or
more with respect to a histological diagnosis of NASH, i.e. fibrosis
and/or inflammation in NAFLD patients. The area under the ROC
curve is 0.82 (95% CI 0.73–0.90). In our study, we defined NASH as
steatohepatitis, whereas borderline NASH and fatty liver were
defined as no NASH. CI, confidence interval; NAFLD, non-alcoholic
fatty liver disease; NASH, non-alcoholic steatohepatitis; ROC,
receiver operating characteristic curve.
Fig. 3. Nomogram of the risk of fibrosis in liver biopsies of 111 NAFLD patients adjusted for BMI. The independent predictors were derived
from the logistic regression analysis to calculate this nomogram. We used the mean value of BMI in our study group (28.2). The probability of
fibrosis was calibrated using the equation: P= eodds of fibrosis/(11eodds of fibrosis). BMI, body mass index; NAFLD, non-alcoholic fatty liver disease.
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This also applies to our study, but it has the advantage
of evaluating both inflammation and fibrosis separately
as well as together, making our data on serum ferritin
much more robust. Our findings are similar and in
accordance to those of a recently published study (55)
evaluating 458 NAFLD patients, in which serum ferritin
was an independent factor for predicting severe fibrosis,
but not in patients with normal ALT values (n= 63).
Our findings suggest that serum ferritin can be used in
the decision making to perform a biopsy in a patient who
by exclusion has NAFLD, and identify as a group those
who have either inflammation or fibrosis or both. Its
potential utility as assessed by AUROC is as good as other
proposed markers, and, when combined with BMI,
diabetes and AST, is better than models in the literature.
Our results confirm those of Bugianesi and colleagues
(36, 37, 55), de Ledinghen (38) that serum ferritin is an
independent factor associated with NASH in NAFLD
patients. Validation of our results as for other studies is
needed, and should be relatively easy as serum ferritin is a
routine test that is already obtained when assessing
chronic liver disease.
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